Hanmi says the WHO listed an international nonproprietary name for its next obesity candidate, following its earlier drug efpeglenatide.
Recap by typeshit. Full story at Health Chosun.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
About 54% of semaglutide users take it to lose weight, per a survey of nearly 15,000 people. 72% of users say they dropped a clothing size.
The post hoc look at 2,300+ women, shown at The Menopause Society meeting, splits results by menopause stage. FDA decision expected late 2026.
Loading…